Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| IIPS#39689 | Other Grant/Funding Number | Merck |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Merck Sharp & Dohme LLC | INDUSTRY |
The purpose of the study is to examine how well three months preceding use of Cerazette progestin only pill predicts the bleeding pattern during following Nexplanon implant use.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Desogestrel, Etonogestrel | Experimental | Arm 1: 75 microgr desogestrel POP (cerazette) daily for 3 months followed by etonogestrel implant (Nexplanon, 68 mg etonogestrel) for following 6 months |
|
| Etonogestrel | Experimental | Arm 2: Women staring straight with Nexplanon implant for 6 months |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Desogestrel 75 micrograms POP (Cerazette), Etonogestrel 68 mg implant (Nexplanon) | Drug | Desogestrel 75 micrograms POP daily for 3 monts, followed by etonogestrel 68 mg subdermal implant for following 6 months |
| Measure | Description | Time Frame |
|---|---|---|
| The total number of bleeding days per 90 days reference period in women using Cerazette before Nexplanon and in women starting Nexplanon without preceding POP | 9 months |
| Measure | Description | Time Frame |
|---|---|---|
| The number of bleeding episodes according to WHO definitions | 9 months |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Dan Apter, Docent | Contact | +358405550842 | dan.apter@vaestoliitto.fi |
| Name | Affiliation | Role |
|---|---|---|
| Dan Apter, Docent | VL-Medi Oy | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| VL Medi Oy | Helsinki | 00101 | Finland |
|
Not provided
| ID | Term |
|---|---|
| D006470 | Hemorrhage |
| ID | Term |
|---|---|
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| D017135 | Desogestrel |
| C044815 | etonogestrel |
| D004343 | Drug Implants |
| ID | Term |
|---|---|
| D009652 | Norpregnenes |
| D009650 | Norpregnanes |
| D009654 | Norsteroids |
| D013256 | Steroids |
| D000072473 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Etonogestrel 68 mg subdermal implant | Drug | Etonogestrel 68 mg subdermal implant for 6 months |
|
| Fused-Ring Compounds |
| D011083 | Polycyclic Compounds |
| D003692 | Delayed-Action Preparations |
| D004304 | Dosage Forms |
| D004364 | Pharmaceutical Preparations |